Campath, Lemtrada (alemtuzumab) is an antibody pharmaceutical. Alemtuzumab was first approved as Campath on 2001-05-07. It is used to treat b-cell chronic lymphocytic leukemia in the USA. It has been approved in Europe to treat multiple sclerosis. The pharmaceutical is active against CAMPATH-1 antigen.
|Indication||b-cell chronic lymphocytic leukemia, multiple sclerosis|
|Drug Class||Monoclonal antibodies: humanized, tumors as target|